Margin recovery masks soft revenue; monsoon dependency remains

PAT 40.6 Cr, representing 104% growth YoY

Revenue 3.9% YoY; well below historical growth; weak

Gross margins improved to 37% from 29% prior year

Confirmed; patented volume growth 37%

Margins strong but revenue flat YoY due to delayed monsoons; 20% sales return provision taken

Prior call: 20% CAGR with CAPEX; now 10-15% organic (CAPEX on hold). Shift to profitability over scale.

Contribution 64% vs 45% prior year; 37% volume growth. Delivered on prior strategy; margin expansion real but top-line lagged.

Reduced ₹764 Cr from ₹812 Cr YoY (-6%); working capital improving. On track vs prior guidance.

₹60 Cr (20% of revenue) pre-provided for Q3-Q4 to counter prior-year Q3-Q4 volatility. Risk mitigation but signals execution caution.

Patented portfolio 37% volume growth; discontinuation of low-margin generics permanent. Margins will sustain as long as patented share stays 60-70% of branded.

Unlikely. Dealers and farmers require generic basket. Patent portfolio will stabilize 60-65%; balance generic. Not going to 80%.

China price crash, B2C launch risks, sales returns, factory capacity on new products. Now recovered and learning. 10-15% CAGR forward.

Yes, under normal circumstances. Achieved 15% before. Confident can repeat 13-14% each year, not specific guidance but reasonable target.

Patented products selling Q1-Q2. Created 20% sales return provision (₹60 Cr) to mitigate Q3-Q4 volatility. Being more conservative this year.

Yes. Raised prices in first week of April and May. Selective increases on patented products. Overall positive; able to pass on most inflation.

Patented ~40% gross margin; generics 15-30%. Significant spread justifies discontinuation focus.

Yes. Rainfall improved from -40% deficit 15 days ago to -15% now. July sales strong. Q2 major quarter; expect good results if monsoons hold.

₹60 Cr (20% expected sales return). Buffer taken at higher gross margin levels to protect profit. Should cover Q3-Q4 volatility.

Revised down from prior 20% CAPEX-dependent target (now on hold). Monsoon and seasonal dependent; management noted not giving specific year targets.

Not hard guidance; positioned as 'reasonable ask' and earlier-achieved level. Contingent on patented portfolio staying 60-70% of branded mix.

Prioritising existing business stabilisation over capacity expansion. Warrant conversion failed (investors didn't pay balance) and QIP closed mid-way. Capacity expansion deferred.

Kharif delayed; seed treatment and herbicide demand compressed Q1. Rabi season hinge on reservoir levels and future rainfall. Management monitoring IMD daily but unable to control outcomes.

Prior 3 years marked by Q3-Q4 sales returns (Kaushik highlighted this pattern). Management provisioning ₹60 Cr (20% of Q1 revenue) pre-emptively. If actual returns exceed provision, Q3-Q4 profits could be materially impacted.

Revenue grew only 3.9% YoY despite 104% PAT growth; prior guidance 20% CAPEX-driven now cut to 10-15% organic. Discontinuation of low-margin generics deliberately suppresses volume. If patented product adoption doesn't accelerate, growth stays capped.

Patented products require field demonstrations, farmer education, digital outreach. If adoption stalls or competitive patented products emerge, margin expansion trajectory broken. Generics discontinued, leaving no volume fallback.

India crop protection market grows only 4-6% CAGR. Company targeting above-market growth via patented/differentiated products, but execution track record volatile (3-year earnings collapse). Pest resistance driving need for newer molecules but competitive intensity high.